ArticleMolecular neurobiology2025
Phosphodiesterase-4 Inhibition: An Experimental Approach to Overcome Drug Resistance in a Rotenone-Corneal 6 Hz Kindling Mouse Model of Drug-Resistant Epilepsy.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel Phosphodiesterase‑2 Inhibitors Discovered via Structure-Based Virtual Screening Targeting the Allosteric GAF‑B Domain.ACS medicinal chemistry letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PDE4 upregulation reduces cAMP levels, leading to disrupted intracellular signaling and increased neuronal hyperexcitability. This contributes to neuroinflammation and neurodegeneration, potentially leading to cognitive decline in drug-resistant epilepsy (DRE) due to persistent seizures. Roflumilast (ROF), a selective PDE4 inhibitor that crosses the blood-brain barrier, comprises several neuroprotective properties. Therefore, this study investigates the therapeutic potential of ROF in a mitochondrial DRE model, i.e., rotenone corneal kindling (RCK). Swiss albino mice underwent for rotenone-corneal kindling for 15 days to induce DRE. Rotenone (2.5 mg/kg, i.p.) 1 h before was followed by corneal shocks (15 mA, 20 V, 6 Hz for 3 s) twice daily with a gap of 4-h. Standard anti-seizure medications (ASMs) such as pregabalin, levetiracetam, carbamazepine, phenytoin, and lamotrigine were used for resistance validation. Drug-resistant mice were then treated with roflumilast (2.5, 5, and 10 mg/kg, p.o.). Post-treatment resistance validation was done, along with cognitive behavior testing. Mice were sacrificed for neurochemical, biochemical, and histological assessments of the hippocampus and cerebral cortex. Drug resistance was confirmed as a non-significant difference in seizure scores was observed with ASMs. Roflumilast effectively treated DRE as it significantly reduced seizure severity and enhanced cognition, especially at higher doses. The restoration of key neuroactive amino acids (GABA, glutamate, tryptophan, glutamine), monoamines (dopamine, noradrenaline, serotonin, Homovanillic acid) and oxidative stress (by reducing TBARS, increasing catalase activity, and elevating glutathione levels) was well correlated with behavioral observations. Histological analysis confirmed neuroprotective effects, highlighting roflumilast's comprehensive benefits in managing DRE. Roflumilast as PDE4 inhibitor significantly manage DRE as evidenced by reducing seizure severity, improving cognitive functions and restoring neurochemical alterations. Its ability to modulate oxidative stress and provide neuroprotection in RCK mice underscores its promise as a novel adjunct treatment for DRE.
Indexed as
Identifiers
41348249What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.